Utah Becomes First State to Allow AI to Issue Prescriptions Without Doctor Review
Utah has granted a narrow exception allowing an AI-based app called Nolla Health to prescribe acne medications directly to patients without mandatory physician oversight, marking the first such authorization in the United States. The one-year pilot program implements a phased approach with varying levels of medical review, starting with physician approval of the first 100 prescriptions and eventually reviewing only 10 percent monthly. The waiver bypasses state law requiring licensed physicians to issue prescriptions and sets a precedent for potentially expanded automated healthcare delivery.
Utah's decision to permit automated prescription issuance represents a significant shift in state medical regulation. The Nolla Health platform operates by analyzing facial imagery to determine acne severity, then integrating this assessment with patient health records to generate medication recommendations. The approval came despite previous concerns about AI applications in healthcare settings, suggesting state regulators found sufficient safeguards in the limited clinical scope and phased rollout structure.
The pilot's oversight architecture reflects a gradual reduction in human review intensity. Early stages maintain robust physician involvement, with complete pre-authorization of initial cases before transitioning to post-pharmacy verification. By the program's final phase, only a monthly sample of prescriptions receives physician examination, creating a substantially different regulatory model than traditional prescription practices.
This authorization could reshape expectations around medication access speed and cost by eliminating physician consultation for certain routine conditions. Patients might benefit from faster prescriptions and potentially lower expenses, while pharmacists gain new quality-control responsibilities. However, the reduced physician oversight in later stages may create concerns about rare adverse reactions going undetected or appropriate contraindications being missed. The precedent established could influence whether other states and condition categories follow suit, potentially expanding or narrowing AI's role in prescription authority based on this pilot's documented outcomes.